|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar
|
|
2
|
El-Serag HB: Hepatocellular carcinoma. N
Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Farazi PA and DePinho RA: Hepatocellular
carcinoma pathogenesis: From genes to environment. Nat Rev Cancer.
6:674–687. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dragani TA: Risk of HCC: Genetic
heterogeneity and complex genetics. J Hepatol. 52:252–257. 2010.
View Article : Google Scholar
|
|
5
|
Lee YH and Yun Y: HBx protein of hepatitis
B virus activates Jak1-STAT signaling. J Biol Chem.
273:25510–25515. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Andrisani OM and Barnabas S: The
transcriptional function of the hepatitis B virus X protein and its
role in hepatocarcinogenesis (Review). Int J Oncol. 15:373–379.
1999.PubMed/NCBI
|
|
7
|
Benn J and Schneider RJ: Hepatitis B virus
HBx protein activates Ras-GTP complex formation and establishes a
Ras, Raf, MAP kinase signaling cascade. Proc Natl Acad Sci USA.
91:10350–10354. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cha MY, Kim CM, Park YM and Ryu WS:
Hepatitis B virus X protein is essential for the activation of
Wnt/beta-catenin signaling in hepatoma cells. Hepatology.
39:1683–1693. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shin JW and Chung Y-H: Molecular targeted
therapy for hepatocellular carcinoma: Current and future. World J
Gastroenterol. 19:6144–6155. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Singal AG, Marrero JA and Singal AG:
Recent advances in the treatment of hepatocellular carcinoma. Curr
Opin Gastroenterol. 26:189–195. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wilhelm SM, Adnane L, Newell P, Villanueva
A, Llovet JM and Lynch M: Preclinical overview of sorafenib, a
multikinase inhibitor that targets both Raf and VEGF and PDGF
receptor tyrosine kinase signaling. Mol Cancer Ther. 7:3129–3140.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al; SHARP Investigators Study Group. Sorafenib in advanced
hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Callegari E, Elamin BK, Sabbioni S,
Gramantieri L and Negrini M: Role of microRNAs in hepatocellular
carcinoma: A clinical perspective. Onco Targets Ther. 6:1167–1178.
2013.PubMed/NCBI
|
|
14
|
Shimokawa N and Yamaguchi M: Molecular
cloning and sequencing of the cDNA coding for a calcium-binding
protein regucalcin from rat liver. FEBS Lett. 327:251–255. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yamaguchi M: The transcriptional
regulation of regucalcin gene expression. Mol Cell Biochem.
346:147–171. 2011. View Article : Google Scholar
|
|
16
|
Yamaguchi M: Role of regucalcin in
maintaining cell homeostasis and function (Review). Int J Mol Med.
15:371–389. 2005.PubMed/NCBI
|
|
17
|
Yamaguchi M: Regucalcin and cell
regulation: Role as a suppressor protein in signal transduction.
Mol Cell Biochem. 353:101–137. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yamaguchi M: Role of regucalcin in cell
nuclear regulation: Involvement as a transcription factor. Cell
Tissue Res. 354:331–341. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yamaguchi M: Suppressive role of
regucalcin in liver cell proliferation: Involvement in
carcinogenesis. Cell Prolif. 46:243–253. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yamaguchi M: The anti-apoptotic effect of
regucalcin is mediated through multisignaling pathways. Apoptosis.
18:1145–1153. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yamaguchi M: Involvement of regucalcin as
a suppressor protein in human carcinogenesis: Insight into the gene
therapy. J Cancer Res Clin Oncol. 141:1333–1341. 2015. View Article : Google Scholar
|
|
22
|
Murata T and Yamaguchi M: Alternatively
spliced variants of the regucalcin gene in various human normal and
tumor tissues. Int J Mol Med. 34:1141–1146. 2014.PubMed/NCBI
|
|
23
|
Misawa H, Inagaki S and Yamaguchi M:
Suppression of cell proliferation and deoxyribonucleic acid
synthesis in the cloned rat hepatoma H4-II-E cells overexpressing
regucalcin. J Cell Biochem. 84:143–149. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yamaguchi M, Osuka S, Weitzmann MN,
El-Rayes BF, Shoji M and Murata T: Prolonged survival in pancreatic
cancer patients with increased regucalcin gene expression:
Overexpression of regucalcin suppresses the proliferation in human
pancreatic cancer MIA PaCa-2 cells in vitro. Int J Oncol.
48:1955–1964. 2016.PubMed/NCBI
|
|
25
|
Yamaguchi M, Osuka S, Weitzmann MN, Shoji
M and Murata T: Increased regucalcin gene expression extends
survival in breast cancer patients: Overexpression of regucalcin
suppresses the proliferation and metastatic bone activity in
MDA-MB-231 human breast cancer cells in vitro. Int J Oncol.
49:812–822. 2016.PubMed/NCBI
|
|
26
|
Shangguan H, Tan S-Y and Zhang J-R:
Bioinformatics analysis of gene expression profiles in
hepatocellular carcinoma. Eur Rev Med Pharmacol Sci. 19:2054–2061.
2015.PubMed/NCBI
|
|
27
|
Wang H-W, Hsieh TH, Huang SY, Chau GY,
Tung CY, Su CW and Wu JC: Forfeited hepatogenesis program and
increased embryonic stem cell traits in young hepatocellular
carcinoma (HCC) comparing to elderly HCC. BMC Genomics. 14:7362013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Uhlen M, Oksvold P, Fagerberg L, Lundberg
E, Jonasson K, Forsberg M, Zwahlen M, Kampf C, Wester K, Hober S,
et al: Towards a knowledge-based Human Protein Atlas. Nat
Biotechnol. 28:1248–1250. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Uhlén M, Fagerberg L, Hallström BM,
Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C,
Sjöstedt E, Asplund A, et al: Proteomics. Tissue-based map of the
human proteome. Science. 347:12604192015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hoshida Y, Villanueva A, Kobayashi M, Peix
J, Chiang DY, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, et
al: Gene expression in fixed tissues and outcome in hepatocellular
carcinoma. N Engl J Med. 359:1995–2004. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Aguirre-Gamboa R, Gomez-Rueda H,
Martínez-Ledesma E, Martínez-Torteya A, Chacolla-Huaringa R,
Rodriguez-Barrientos A, Tamez-Peña JG and Treviño V: SurvExpress:
An online biomarker validation tool and database for cancer gene
expression data using survival analysis. PLoS One. 8:e742502013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yamaguchi M and Daimon Y: Overexpression
of regucalcin suppresses cell proliferation in cloned rat hepatoma
H4-II-E cells: Involvement of intracellular signaling factors and
cell cycle-related genes. J Cell Biochem. 95:1169–1177. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nakagawa T, Sawada N and Yamaguchi M:
Overexpression of regucalcin suppresses cell proliferation of
cloned normal rat kidney proximal tubular epithelial NRK52E cells.
Int J Mol Med. 16:637–643. 2005.PubMed/NCBI
|
|
34
|
Izumi T and Yamaguchi M: Overexpression of
regucalcin suppresses cell death in cloned rat hepatoma H4-II-E
cells induced by tumor necrosis factor-alpha or thapsigargin. J
Cell Biochem. 92:296–306. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liang C-C, Park AY and Guan J-L: In vitro
scratch assay: A convenient and inexpensive method for analysis of
cell migration in vitro. Nat Protoc. 2:329–333. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Meijer L, Borgne A, Mulner O, Chong JP,
Blow JJ, Inagaki N, Inagaki M, Delcros JG and Moulinoux JP:
Biochemical and cellular effects of roscovitine, a potent and
selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and
cdk5. Eur J Biochem. 243:527–536. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Singh SV, Herman-Antosiewicz A, Singh AV,
Lew KL, Srivastava SK, Kamath R, Brown KD, Zhang L and Baskaran R:
Sulforaphane-induced G2/M phase cell cycle arrest involves
checkpoint kinase 2-mediated phosphorylation of cell division cycle
25C. J Biol Chem. 279:25813–25822. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Serrano-Nascimento C, da Silva Teixeira S,
Nicola JP, Nachbar RT, Masini-Repiso AM and Nunes MT: The acute
inhibitory effect of iodide excess on sodium/iodide symporter
expression and activity involves the PI3K/Akt signaling pathway.
Endocrinology. 155:1145–1156. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chen S, Wang Y, Ruan W, Wang X and Pan C:
Reversing multidrug resistance in hepatocellular carcinoma cells by
inhibiting extracellular signal-regulated kinase/mitogen-activated
protein kinase signaling pathway activity. Oncol Lett. 8:2333–2339.
2014.PubMed/NCBI
|
|
40
|
Palangat M, Grass JA, Langelier MF,
Coulombe B and Landick R: The RPB2 flap loop of human RNA
polymerase II is dispensable for transcription initiation and
elongation. Mol Cell Biol. 31:3312–3325. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tang SC and Chen YC: Novel therapeutic
targets for pancreatic cancer. World J Gastroenterol.
20:10825–10844. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Tsurusaki Y and Yamaguchi M: Role of
regucalcin in liver nuclear function: Binding of regucalcin to
nuclear protein or DNA and modulation of tumor-related gene
expression. Int J Mol Med. 14:277–281. 2004.PubMed/NCBI
|
|
43
|
Yamaguchi M and Sakurai T: Inhibitory
effect of calcium-binding protein regucalcin on
Ca2+-activated DNA fragmentation in rat liver nuclei.
FEBS Lett. 279:281–284. 1991. View Article : Google Scholar : PubMed/NCBI
|
